摘要
顽固性高血压在临床中越来越常见,相关并发症的风险较高,有较高的致残率及致死率。临床治疗过程中,需结合患者自身情况,选择不同的降压药物联合应用。血管紧张素转换酶抑制剂及血管紧张素Ⅱ受体阻滞剂作为肾素-血管紧张素系统中的两大主要降压药物,作用机制及作用位点并不相同,临床获益存在差异。了解血管紧张素转换酶抑制剂及血管紧张素Ⅱ受体阻滞剂联合应用的作用机制,治疗顽固性高血压的协同效应,分析其有效性和安全性,可为联合用药提供借鉴。
Resistant hypertension is one of the commonest diseases with high disability and high fatality rate in clinical practice,and the risk of related complication is high.In the course of clinical treatment,the combinations of antihypertensive drugs should consider the patient′s own situation.Angiotensin-converting enzyme inhibitors(ACEI)and angiotensinⅡreceptor blocker(ARB)drugs are the two main antihypertensive drugs in renin angiotensin system,and the mechanism and site of action and clinical benefits are different.Understanding the mechanism combined application of ACEI and ARB,the synergistic effect,and analyzing its effectiveness and safety can provide reference for the combined medication.
作者
曲文博
李学奇
QU Wenbo;LI Xueqi(Department of Cardiology,the Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《医学综述》
2018年第13期2627-2631,共5页
Medical Recapitulate